Organic compounds

Patent metadata

Field	Value
Publication number	US-2016039835-A1
Application number	US-201414777446-A
Country	US
Kind code	A1
Filing date	Mar 13, 2014
Priority date	Mar 15, 2013
Publication date	Feb 11, 2016
Grant date	—

Abstract

Provided are PDE1 inhibitors of Formula I, processes for their production and their use as pharmaceuticals, and pharmaceutical compositions comprising them.

First claim

1 . A compound of Formula I:

wherein
(i) R 1 is H or C 1-4 alkyl;
(ii) R 2 and R 3 are independently H or C 1-6 alkyl;
(iii) R 4 is H or C 1-4 alkyl;
(iv) R 5 is aryl optionally substituted with one or more groups independently selected from —C(═O)—C 1-6 alkyl and C 1-6 -hydroxyalkyl;
(v) R 6 and R 7 are independently H; aryl optionally substituted with one or more groups independently selected from C 1-6 alkyl and halogen, unsubstituted phenyl; phenyl substituted with one or more halogen; phenyl substituted with one or more C 1-6 alkyl and one or more halogen; or phenyl substituted with one C 1-6 alkyl and one halogen; and
(vi) n is 1, 2, 3, or 4,

in free or salt form.

2 . The compound according to claim 1 , wherein the compound is a compound of Formula I(i):

wherein
(i) R 1 is H or C 1-4 alkyl;
(ii) R 2 and R 3 are independently H or C 1-6 alkyl;
(iii) R 4 is H or C 1-4 alkyl;
(iv) R 5 is aryl optionally substituted with one or more groups independently selected from —C(═O)—C 1-6 alkyl and C 1-6 -hydroxyalkyl;
(v) R 6 and R 7 are independently H; aryl optionally substituted with one or more groups independently selected from C 1-6 alkyl and halogen; unsubstituted phenyl; phenyl substituted with one or more halogen; phenyl substituted with one or more C 1-6 alkyl and one or more halogen; or phenyl substituted with one C 1-6 alkyl and one halogen; and
(vi) n is 1, 2, 3, or 4,

in free or salt form.

3 . The compound according to claim 2 , wherein the compound is a compound of Formula I(ii):

wherein
(i) R 1 is H or C 1-4 alkyl;
(ii) R 2 and R 3 are independently H or C 1-6 alkyl;
(iii) R 4 is H or C 1-4 alkyl;
(iv) R 5 is aryl optionally substituted with one or more groups independently selected from —C(═O)—C 1-6 alkyl and C 1-6 -hydroxyalkyl; and
(v) R 6 and R 7 are independently H; aryl optionally substituted with one or more groups independently selected from C 1-6 alkyl and halogen; unsubstituted phenyl; phenyl substituted with one or more halogen; phenyl substituted with one or more C 1-6 alkyl and one or more halogen; or phenyl substituted with one C 1-6 alkyl and one halogen,

in free or salt form.

4 . The compound according to claim 2 , wherein
(i) R 1 is C 1-4 alkyl; (ii) R 2 and R 3 are independently C 1-6 alkyl; (iii) R 4 is H; (iv) R 5 is aryl substituted with one or more groups independently selected from —C(═O)—C 1-6 alkyl and C 1-6 -hydroxyalkyl; (v) R 6 is aryl substituted with one or more groups independently selected from C 1-6 alkyl; halogen; phenyl substituted with one or more halogen; phenyl substituted with one or more C 1-6 alkyl and one or more halogen; or phenyl substituted with one C 1-6 alkyl and one halogen; and (vi) R 7 is H,
in free or salt form.

5 . The compound according to claim 2 , wherein the compound is selected from

in free or salt form.

6 . A pharmaceutical composition comprising a compound according to claim 1 , in free or pharmaceutically acceptable salt form, in admixture with a pharmaceutically acceptable diluent or carrier.

7 . A method of treating any of the following conditions: Parkinson's disease, restless leg, tremors, dyskinesias, Huntington's disease, Alzheimer's disease, drug-induced movement disorders, depression, attention deficit disorder, attention deficit hyperactivity disorder, bipolar illness, anxiety, sleep disorder, narcolepsy, cognitive impairment, e.g., cognitive impairment of schizophrenia, dementia, Tourette's syndrome, autism, fragile X syndrome, psychostimulant withdrawal, drug addiction, cerebrovascular disease, stroke, congestive heart disease, hypertension, pulmonary hypertension, sexual dysfunction, asthma, chronic obstructive pulmonary disease, allergic rhinitis, autoimmune diseases, inflammatory diseases, female sexual dysfunction, exercise amenorrhoea, anovulation, menopause, menopausal symptoms, hypothyroidism, pre-menstrual syndrome, premature labor, infertility, irregular menstrual cycles, abnormal uterine bleeding, osteoporosis, multiple sclerosis, prostate enlargement, prostate cancer, hypothyroidism, estrogen-induced endometrial hyperplasia or carcinoma, glaucoma, elevated intraocular pressure, psychosis, e.g., schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, and mania, such as in acute manic episodes and bipolar disorder, traumatic brain injury, and/or any disease or condition characterized by low levels of cAMP and/or cGMP (or inhibition of cAMP and/or cGMP signaling pathways) in cells expressing PDE1, and/or by reduced dopamine D1 receptor signaling activity, and/or any disease or condition that may be ameliorated by the enhancement of progesterone signaling, comprising administering an effective amount of a compound according to claim 1 , in free or pharmaceutically acceptable salt form to a patient in need thereof.

8 . The method of claim 7 , wherein the condition is Parkinson's disease.

9 . The method of claim 7 , wherein the condition is cognitive impairment.

10 . The method of claim 7 , wherein the condition is cognitive impairment of schizophrenia.

11 . The method of claim 7 , wherein the condition is narcolepsy.

12 . The method of claim 11 further comprising administering one or more compounds selected from central nervous system stimulants, modafinil, antidepressants, and gamma hydroxybutyrate, to a patient in need thereof.

13 . The method of claim 7 , wherein the condition is female sexual dysfunction.

14 . The method of claim 13 , further comprising administering one or more compounds selected from estradiol, estriol, estradiol esters, progesterone and progestins, to a patient in need thereof.

15 . A method for the treatment of glaucoma or elevated intraocular pressure comprising topical administration of an effective amount of a compound according to claim 1 , in free or pharmaceutically acceptable salt form, in an ophthalmically compatible carrier to the eye of a patient in need thereof.

16 . A method for the treatment of traumatic brain injury comprising administering an effective amount of a compound according to claim 1 , in free or pharmaceutically acceptable salt form, to a patient in need thereof.

17 . A method for lengthening or enhancing growth of the eyelashes comprising administering an effective amount of a prostaglandin analogue, e.g., bimatoprost, concomitantly, simultaneously or sequentially with an effective amount of a compound according to claim 1 , in free or pharmaceutically acceptable salt form.

18 . (canceled)

19 . (canceled)

20 . A pharmaceutical composition comprising a compound according to claim 1 in free or pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier for use in the treatment or prophylactic treatment of any of the following conditions: Parkinson's disease, restless leg, tremors, dyskinesias, Huntington's disease, Alzheimer's disease, drug-induced movement disorders, depression, attention deficit

Assignees

• Intra Cellular Therapies Inc

Inventors

• Li Peng
• Zheng Hailin
• Zhao Jun
• Wennogle Lawrence

Classifications

• A61P5/24

  of the sex hormones · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/30

  for treating abuse or dependence · CPC title

• A61P25/26

  Psychostimulants, e.g. nicotine, cocaine · CPC title